Payer decision making for next-generation sequencing-based genetic tests: Insights from cell-free DNA prenatal screening

Andrew P. Dervan, Patricia A. Deverka, Julia R. Trosman, Christine B. Weldon, Michael P. Douglas, Kathryn A. Phillips

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose:Cell-free DNA (cfDNA) prenatal screening tests have been rapidly adopted into clinical practice, due in part to positive insurance coverage. We evaluated the framework payers used in making coverage decisions to describe a process that should be informative for other sequencing tests.Methods:We analyzed coverage policies from the 19 largest US private payers with publicly available policies through February 2016, building from the University of California San Francisco TRANSPERS Payer Coverage Policy Registry.Results:All payers studied cover cfDNA screening for detection of trisomies 21, 18, and 13 in high-risk, singleton pregnancies, based on robust clinical validity (CV) studies and modeled evidence of clinical utility (CU). Payers typically evaluated the evidence for each chromosomal abnormality separately, although results are offered as part of a panel. Starting in August 2015, 8 of the 19 payers also began covering cfDNA screening in average-risk pregnancies, citing recent CV studies and updated professional guidelines. Most payers attempted, but were unable, to independently assess analytic validity (AV).Conclusion:Payers utilized the standard evidentiary framework (AV/CV/CU) when evaluating cfDNA screening but varied in their interpretation of the sufficiency of the evidence. Professional guidelines, large CV studies, and decision analytic models regarding health outcomes appeared highly influential in coverage decisions.

Original languageEnglish (US)
Pages (from-to)559-567
Number of pages9
JournalGenetics in Medicine
Volume19
Issue number5
DOIs
StatePublished - May 1 2017

Keywords

  • cell-free DNA
  • clinical utility
  • insurance coverage
  • next-generation sequencing
  • noninvasive prenatal testing

ASJC Scopus subject areas

  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Payer decision making for next-generation sequencing-based genetic tests: Insights from cell-free DNA prenatal screening'. Together they form a unique fingerprint.

Cite this